Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPN | P05981 | 16/20 | 0.83 |
| ▸ | ST14 | Q9Y5Y6 | 16/20 | 0.83 |
| ▸ | TMPRSS2 | O15393 | 14/20 | 0.83 |
| ▸ | HGFAC | Q04756 | 14/20 | 0.83 |
| ▸ | F2 | P00734 | 14/20 | 0.83 |
| ▸ | F10 | P00742 | 5/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593146 | 1.00 | HPN (0.83) | HPNST14TMPRSS2HGFACF2 | |
| SCHEMBL31593114 | 0.94 | HPN (0.84) | HPNST14TMPRSS2HGFACF2 | |
| SCHEMBL31593144 | 0.91 | HPN (0.84) | HPNST14TMPRSS2HGFACF2 | |
| SCHEMBL31593103 | 0.91 | HPN (0.84) | HPNST14TMPRSS2HGFACF2 | |
| SCHEMBL22849994 | 0.91 | HPN (0.84) | HPNST14TMPRSS2HGFACF2 | |
| SCHEMBL31593121 | 0.91 | HPN (0.84) | HPNST14TMPRSS2HGFACF2 | |
| SCHEMBL22850375 | 0.91 | HPN (0.84) | HPNST14TMPRSS2HGFACF2 | |
| SCHEMBL22834081 | 0.88 | HPN (0.65) | HPNST14TMPRSS2HGFACF2 | |
| SCHEMBL22834079 | 0.88 | HPN (0.65) | HPNST14TMPRSS2HGFACF2 | |
| SCHEMBL31593139 | 0.85 | HPN (0.83) | HPNST14TMPRSS2HGFACF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | TMPRSS2, PRSS1, PRSS2 | HPN 13/4885ST14 84/4885TMPRSS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.